| Drug Name |
Cilostazol |
| Drug ID |
BADD_D00466 |
| Description |
Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. |
| Indications and Usage |
Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest). |
| Marketing Status |
approved; investigational |
| ATC Code |
B01AC23 |
| DrugBank ID |
DB01166
|
| KEGG ID |
D01896
|
| MeSH ID |
D000077407
|
| PubChem ID |
2754
|
| TTD Drug ID |
D03VPC
|
| NDC Product Code |
70518-2208; 66039-113; 50268-177; 0054-0028; 46438-0633; 0093-2065; 70436-157; 0054-0044; 63629-8795; 71610-037; 70436-156; 46438-1109; 42291-453; 50090-5329; 60505-2521; 58175-0379; 63415-0034; 60505-2522; 63629-8796; 72189-116; 46438-0632; 50268-176; 70518-2714; 42185-7038; 0093-2064 |
| UNII |
N7Z035406B
|
| Synonyms |
Cilostazol | 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone | OPC 13013 | OPC-13013 | Pletal |
